Literature DB >> 17720892

Etiology and natural history of diabetic retinopathy: an overview.

Candis M Morello1.   

Abstract

PURPOSE: The morbidity and mortality from and economic impact of diabetes mellitus in the United States, pathogenesis of microvascular diabetic complications, contribution of poor long-term glycemic control to risk for diabetic retinopathy and other microvascular complications, prevalence of diabetic retinopathy, methods for measuring visual acuity, and manifestations of disease progression and etiology of blindness in patients with diabetic retinopathy are discussed.
SUMMARY: Diabetic retinopathy and other microvascular and macrovascular complications of diabetes cause considerable morbidity and mortality and have a large economic impact in the United States. Patients with poor long-term glycemic control are more vulnerable to diabetic retinopathy than to other microvascular complications of diabetes. Diabetic retinopathy is the third leading cause of all cases of blindness in the United States and the leading cause of new cases in adults. Retinopathy is already present at the time of diagnosis in 20% of patients with type 2 diabetes. Retinopathy and other micro-vascular complications are attributed to chronic hyperglycemia, vascular damage and leakage, edema, capillary basement membrane thickening, neovascularization, hemorrhage, and ischemia. Measurements of visual acuity loss are expressed in terms of the distance at which a person with normal vision can see what the test subject can see from 20 feet away. Diabetic retinopathy begins as nonproliferative abnormalities and progresses to proliferative diabetic retinopathy. Macular edema can develop at any time in the progression of diabetic retinopathy. Macular ischemia, retinal and vitreous hemorrhage, and retinal detachment are the primary causes of blindness in patients with diabetic retinopathy.
CONCLUSION: Diabetic retinopathy is a costly and progressive condition associated with chronic hyperglycemia. It is potentially vision-threatening.

Entities:  

Mesh:

Year:  2007        PMID: 17720892     DOI: 10.2146/ajhp070330

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  19 in total

Review 1.  Notch signaling in ocular vasculature development and diseases.

Authors:  Guo-Rui Dou; Lin Wang; Yu-Sheng Wang; Hua Han
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

2.  Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

Authors:  Ashay D Bhatwadekar; Viral S Kansara; Thomas A Ciulla
Journal:  Expert Opin Investig Drugs       Date:  2020-01-31       Impact factor: 6.206

Review 3.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 4.  Diabetic retinopathy: Breaking the barrier.

Authors:  Randa S Eshaq; Alaa M Z Aldalati; J Steven Alexander; Norman R Harris
Journal:  Pathophysiology       Date:  2017-07-12

5.  Retinopathy screening in patients with type 1 diabetes diagnosed in young age using a non-mydriatic digital stereoscopic retinal imaging.

Authors:  N Minuto; V Emmanuele; M Vannati; C Russo; C Rebora; S Panarello; A Pistorio; R Lorini; G d'Annunzio
Journal:  J Endocrinol Invest       Date:  2011-10-06       Impact factor: 4.256

Review 6.  Glycobiology of ocular angiogenesis.

Authors:  Anna I Markowska; Zhiyi Cao; Noorjahan Panjwani
Journal:  Glycobiology       Date:  2014-08-08       Impact factor: 4.313

Review 7.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

8.  Diabetic Retinopathy: Focus on Minority Populations.

Authors:  Arpine Barsegian; Boleslav Kotlyar; Justin Lee; Moro O Salifu; Samy I McFarlane
Journal:  Int J Clin Endocrinol Metab       Date:  2017-11-11

9.  Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.

Authors:  Jayoung Kim; Raquel Lima E Silva; Ron B Shmueli; Adam C Mirando; Stephany Y Tzeng; Niranjan B Pandey; Elana Ben-Akiva; Aleksander S Popel; Peter A Campochiaro; Jordan J Green
Journal:  Acta Biomater       Date:  2019-07-30       Impact factor: 8.947

Review 10.  PlGF: a multitasking cytokine with disease-restricted activity.

Authors:  Mieke Dewerchin; Peter Carmeliet
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.